Why the study?
The prevalence and role of autoantibodies targeting the endogenous IL-1 receptor antagonist in patients with recurrent pericarditis with an inflammatory phenotype were unknown.
What is the prevalence and role of autoantibodies targeting the endogenous interleukin 1 (IL-1) receptor antagonist in patients with recurrent pericarditis with an inflammatory phenotype?
Population
Patients with recurrent pericarditis with an inflammatory phenotype
Design
Cohort study
Key result
Autoantibodies targeting the endogenous interleukin 1 receptor antagonist were evaluated for their prevalence and clinical role in patients with inflammatory recurrent pericarditis.
Authors
Loading...
Hypothesis-generating for IL-1 antagonism in inflammatory recurrent pericarditis; prospective trials needed before practice change.
What is the prevalence and role of autoantibodies targeting the endogenous interleukin 1 (IL-1) receptor antagonist in patients with recurrent pericarditis with an inflammatory phenotype?
This study investigates the presence of IL-1 receptor antagonist autoantibodies in idiopathic recurrent pericarditis, which may provide insights into its underlying pathophysiology.
Wu et al. (2025) studied this question. Autoantibodies targeting the endogenous interleukin 1 receptor antagonist were evaluated for their prevalence and clinical role in patients with inflammatory recurrent pericarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: